Natural Biocon India Limited Conducts Independent Directors Meeting on March 20, 2026

Natural Biocon India Limited has announced the successful completion of its independent directors meeting held on March 20, 2026, in accordance with regulatory requirements under the SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015.

Meeting Details and Compliance

The meeting was conducted pursuant to Regulation 25(3) of the Securities and Exchange Board of India (LODR) Regulations, 2015, read with Schedule IV of the Companies Act, 2013. This annual meeting represents a mandatory governance requirement for listed companies to ensure independent oversight of board operations.

Parameter:	Details
Meeting Date:	March 20, 2026
Duration:	02:00 P.M. to 03:15 P.M.
Venue:	Registered Office
Regulatory Framework:	SEBI LODR Regulations, 2015

Key Agenda Items Reviewed

The independent directors present at the meeting transacted several critical governance matters as part of their oversight responsibilities. The meeting agenda encompassed comprehensive performance evaluations and assessments across multiple dimensions of board effectiveness.

The directors undertook the following key activities:

Board Performance Review: Comprehensive evaluation of non-independent directors and assessment of the board of directors' collective performance
Chairperson Assessment: Detailed review of the chairperson's performance, incorporating perspectives from both executive and non-executive directors
Information Flow Analysis: Critical assessment of the quality, quantity, and timeliness of information exchange between company management and the board of directors

Governance and Transparency

This independent directors meeting forms part of Natural Biocon India Limited's commitment to maintaining robust corporate governance standards. The evaluation process ensures that the board operates effectively and that directors have access to necessary information for informed decision-making.

The company has duly informed BSE Limited about the meeting outcome, maintaining transparency with stakeholders and regulatory compliance. The notification was signed by Managing Director Arunkumar Prajapati (DIN: 08281232), confirming the completion of this mandatory governance exercise for Financial Year 2025-26.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-4.76%	-24.53%	-15.09%	-37.72%	-75.54%	-77.98%

Natural biocon (India) Limited has announced its unaudited financial results for the third quarter ended December 31, 2025, revealing a challenging operational period with zero revenue generation. The Board of Directors approved these results during their meeting held on February 13, 2026.

Financial Performance Overview

The company's Q3FY26 performance showed a stark contrast to the previous year's corresponding quarter. Key financial metrics demonstrate the operational challenges faced during this period.

Metric	Q3FY26 (₹ Lakhs)	Q3FY25 (₹ Lakhs)	Change
Net Sales/Income from Operations	0.00	127.73	-100%
Total Expenses	4.27	103.14	-95.86%
Net Profit/(Loss)	(4.27)	24.59	Loss
Basic EPS (₹)	(0.02)	0.10	Negative

Quarterly Operational Analysis

The third quarter of FY26 witnessed complete absence of operational revenue, with the company recording zero income from operations. This represents a significant departure from the ₹127.73 lakhs revenue generated in Q3FY25. Despite the revenue decline, the company maintained minimal operational expenses totaling ₹4.27 lakhs.

Expense management during the quarter included employee benefits expense of ₹1.23 lakhs, other expenditure of ₹2.94 lakhs, and depreciation of ₹0.10 lakhs. The company reported no financial costs, material consumption, or stock-in-trade purchases during this period.

Nine-Month Performance Comparison

The year-to-date figures for the nine months ended December 31, 2025, provide additional context to the company's performance trajectory.

Parameter	9M FY26 (₹ Lakhs)	9M FY25 (₹ Lakhs)	Variance
Revenue from Operations	166.57	601.42	-72.30%
Total Expenses	161.34	556.59	-71.02%
Net Profit	5.23	44.83	-88.33%
Basic EPS (₹)	0.02	0.17	-88.24%

For the nine-month period, Natural Biocon achieved revenue of ₹166.57 lakhs compared to ₹601.42 lakhs in the corresponding period of FY25. The company managed to maintain profitability with a net profit of ₹5.23 lakhs, though this represents a substantial decline from the ₹44.83 lakhs profit recorded in the previous year.

Corporate Governance and Compliance

The financial results were reviewed by the Audit Committee and approved by the Board of Directors during their meeting on February 13, 2026. The results have been prepared in accordance with Indian Accounting Standards specified under Section 133 of the Companies Act, 2013, and comply with Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015.

Mayur Shah & Associates, Chartered Accountants, conducted the limited review of these unaudited financial results. The company maintains a paid-up equity share capital of ₹2,578.28 lakhs with a face value of ₹10 per share, which remained unchanged throughout the reporting periods.

Key Financial Highlights

Zero operational revenue in Q3FY26 versus ₹127.73 lakhs in Q3FY25
Net loss of ₹4.27 lakhs in Q3FY26 compared to profit of ₹24.59 lakhs in Q3FY25
Nine-month revenue declined 72.30% to ₹166.57 lakhs
Earnings per share turned negative at ₹(0.02) for Q3FY26
Company operates in a single business segment

The results indicate Natural Biocon faced significant operational challenges during the third quarter, with the absence of revenue generation leading to losses despite controlled expense management.